We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.

Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.

France-based pharmaceutical company Sanofi stated Monday that it will acquire US-based Blueprint Medicines Corporation for $9.1 billion to expand its portfolio in rare immunological diseases ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has ...

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.

In other recent news, Blueprint Medicines has reported a surprising first-quarter 2025 earnings per share of $0.01, significantly surpassing the forecasted -$0.49.

Sanofi acquires Blueprint Medicines for $9.1 billion, gaining Ayvakit, a rare disease treatment approved in the US and EU for multiple conditions.

Sanofi SAN-1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Investing.com -- Shares of Blueprint Medicines Corp (NASDAQ: BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (EPA: SASY) (NASDAQ: SNY) in a ...